Oncol-话题@MedSci

#Oncol#

2384篇内容 | 3442人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866704, encodeId=1f3f1866e04fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, objectType=article, longId=738547, objectId=dd49e385472d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd49e385472d, replyNumber=0, likeNumber=112, createdTime=2023-06-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd49e385472d, moduleTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd49e385472d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866708, encodeId=3d841866e0870, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）, objectType=article, longId=738964, objectId=ad9ce38964d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9ce38964d4, replyNumber=0, likeNumber=163, createdTime=2023-02-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9ce38964d4, moduleTitle=Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad9ce38964d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866705, encodeId=4f4f1866e05a6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后, objectType=article, longId=738555, objectId=c150e3855510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c150e3855510, replyNumber=0, likeNumber=158, createdTime=2023-03-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c150e3855510, moduleTitle=JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c150e3855510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866695, encodeId=104818666951b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, objectType=article, longId=737430, objectId=dbc4e37430eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc4e37430eb, replyNumber=0, likeNumber=134, createdTime=2022-10-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc4e37430eb, moduleTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbc4e37430eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866696, encodeId=a805186669618, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, objectType=article, longId=737431, objectId=c616e3743158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c616e3743158, replyNumber=0, likeNumber=118, createdTime=2022-12-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c616e3743158, moduleTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c616e3743158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866692, encodeId=57a2186669293, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, objectType=article, longId=736189, objectId=c485e36189fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c485e36189fd, replyNumber=0, likeNumber=113, createdTime=2022-09-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c485e36189fd, moduleTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c485e36189fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866706, encodeId=cb621866e06b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Radiother Oncol：电子束放疗的生物有效剂量对瘢痕疙瘩切除术后复发率的影响, objectType=article, longId=738804, objectId=9605e3880467, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9605e3880467, replyNumber=0, likeNumber=130, createdTime=2023-07-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9605e3880467, moduleTitle=Radiother Oncol：电子束放疗的生物有效剂量对瘢痕疙瘩切除术后复发率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9605e3880467)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866694, encodeId=5d7d18666949b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Gynecol Oncol：治疗前中性粒细胞与淋巴细胞的比率与子宫内膜癌患者的 OS 相关, objectType=article, longId=736916, objectId=1a2ce36916d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2ce36916d6, replyNumber=0, likeNumber=100, createdTime=2023-05-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2ce36916d6, moduleTitle=Gynecol Oncol：治疗前中性粒细胞与淋巴细胞的比率与子宫内膜癌患者的 OS 相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a2ce36916d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866629, encodeId=4d011866629ec, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后, objectType=article, longId=728872, objectId=66cae28872f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cae28872f3, replyNumber=0, likeNumber=122, createdTime=2022-07-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cae28872f3, moduleTitle=J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cae28872f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866657, encodeId=7057186665e35, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, objectType=article, longId=731832, objectId=22efe318328a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22efe318328a, replyNumber=0, likeNumber=130, createdTime=2023-02-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22efe318328a, moduleTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22efe318328a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866645, encodeId=911d18666454e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤, objectType=article, longId=729993, objectId=904fe29993ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904fe29993ee, replyNumber=0, likeNumber=116, createdTime=2022-10-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904fe29993ee, moduleTitle=J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904fe29993ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866671, encodeId=7e0818666e159, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, objectType=article, longId=734106, objectId=f1c8e341064d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1c8e341064d, replyNumber=0, likeNumber=122, createdTime=2022-08-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1c8e341064d, moduleTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1c8e341064d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866668, encodeId=b169186666800, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, objectType=article, longId=732817, objectId=fd3ce32817fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3ce32817fa, replyNumber=0, likeNumber=126, createdTime=2023-01-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3ce32817fa, moduleTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3ce32817fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866662, encodeId=13981866662af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, objectType=article, longId=732583, objectId=f259e3258327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f259e3258327, replyNumber=0, likeNumber=128, createdTime=2022-08-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f259e3258327, moduleTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f259e3258327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866631, encodeId=47a1186663130, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=729045, objectId=c007e2904512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c007e2904512, replyNumber=0, likeNumber=100, createdTime=2022-11-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c007e2904512, moduleTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c007e2904512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866625, encodeId=6e7b18666255e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌, objectType=article, longId=728692, objectId=12f8e28692da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f8e28692da, replyNumber=0, likeNumber=140, createdTime=2023-05-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f8e28692da, moduleTitle=JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f8e28692da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866703, encodeId=51b31866e0308, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, objectType=article, longId=738663, objectId=5cfee38663b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfee38663b9, replyNumber=0, likeNumber=131, createdTime=2022-11-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfee38663b9, moduleTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfee38663b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866681, encodeId=129c18666817b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤, objectType=article, longId=735293, objectId=8390e3529363, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8390e3529363, replyNumber=0, likeNumber=127, createdTime=2023-02-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8390e3529363, moduleTitle=Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8390e3529363)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866700, encodeId=7c081866e00d1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效, objectType=article, longId=738665, objectId=219ae3866547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=219ae3866547, replyNumber=0, likeNumber=124, createdTime=2023-06-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=219ae3866547, moduleTitle=J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=219ae3866547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866679, encodeId=dc6318666e921, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, objectType=article, longId=734229, objectId=6890e34229fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6890e34229fe, replyNumber=0, likeNumber=150, createdTime=2023-01-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6890e34229fe, moduleTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6890e34229fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌

2023-06-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：叶定伟教授团队发现瑞维鲁胺治疗转移性激素敏感性前列腺癌疗效显著！（CHART研究）

2023-02-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后

2023-03-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效

2022-10-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌

2022-12-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌

2022-09-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Radiother Oncol：电子束放疗的生物有效剂量对瘢痕疙瘩切除术后复发率的影响

2023-07-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Gynecol Oncol：治疗前中性粒细胞与淋巴细胞的比率与子宫内膜癌患者的 OS 相关

2023-05-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后

2022-07-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌

2023-02-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤

2022-10-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病

2022-08-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识

2023-01-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析

2022-08-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌

2022-11-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Abemaciclib联合内分泌治疗高风险早期乳腺癌

2023-05-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性

2022-11-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：阿特珠单抗+Cobimetinib+Vemurafenib治疗CNS转移的黑色素瘤

2023-02-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效

2023-06-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤

2023-01-29

科室
- - 订阅+
  - 更多科室
工具
服务